Red wine ingredient resveratrol stops breast cancer growth

September 29, 2011

Cheers! A new research report appearing in the October 2011 issue of The FASEB Journal shows that resveratrol, the "healthy" ingredient in red wine, stops breast cancer cells from growing by blocking the growth effects of estrogen. This discovery, made by a team of American and Italian scientists, suggests for the first time that resveratrol is able to counteract the malignant progression since it inhibits the proliferation of hormone resistant breast cancer cells. This has important implications for the treatment of women with breast cancer whose tumors eventually develop resistance to hormonal therapy.

"Resveratrol is a potential pharmacological tool to be exploited when become resistant to the hormonal therapy," said Sebastiano Andò, a researcher involved in the work from the Faculty of Pharmacy at the University of Calabria in Italy.

To make this discovery, Andò and colleagues used several breast cancer cell lines expressing the estrogen receptor to test the effects of resveratrol. Researchers then treated the different cells with resveratrol and compared their growth with cells left untreated. They found an important reduction in cell growth in cells treated by resveratrol, while no changes were seen in untreated cells. Additional experiments revealed that this effect was related to a drastic reduction of estrogen receptor levels caused by resveratrol itself.

"These findings are exciting, but in no way does it mean that should people go out and start using red wine or resveratrol supplements as a treatment for breast cancer," said Gerald Weissmann, M.D., Editor-in-Chief of The . "What it does mean, however, is that scientists haven't finished distilling the secrets of good health that have been hidden in natural products such as red wine."

Explore further: Red wine: Exercise in a bottle?

More information: Francesca De Amicis, Francesca Giordano, Adele Vivacqua, Michele Pellegrino, Maria Luisa Panno, Donatella Tramontano, Suzanne A. W. Fuqua, and Sebastiano Andò. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 2011 25:3695-3707; doi:10.1096/fj.10-178871

Related Stories

Red wine: Exercise in a bottle?

June 30, 2011
As strange as it sounds, a new research study published in the FASEB Journal, suggests that the "healthy" ingredient in red wine, resveratrol, may prevent the negative effects that spaceflight and sedentary lifestyles have ...

Recommended for you

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

rsklyar
not rated yet Oct 02, 2011
How young ambitious capos and soldiers from Italian Institute of Technology (IIT) under supervision of a decrepit american don-godfather from Northwestern University are successfully completed their sequential plagiaristic enterprise: http://issuu.com/...saivaldi

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.